Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

Shares of this drugmaker have returned -19.4% over the past month versus the Zacks S&P 500 composite's -12.2% change. The Zacks Large Cap Pharmaceuticals industry, to which Novo Nordisk belongs ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s ...

Tradewinds Capital Management LLC increased its position in shares of Novo Nordisk A/S by 2.6% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s ...

Also Read: Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech The trial also demonstrated superiority to placebo for all confirmatory secondary outcomes assessed ...

Tiden hvor Novo Nordisk havde en markedsværdi på mere end 4000 mia. kr. , synes som en fjern fortid. Novo Nordisk-aktien er på vej mod sit største månedlige fald i mere end 20 år og har i marts ...